Innoviva, Inc. (INVA)

NMS – Real Time Price. Currency in USD

23.57

+0.22 (0.94%)

At close: Jun 26, 2026, 4:00 PM EDT

23.57

-0.00 (-0.00%)

After-hours: Jun 26, 2026, 4:31 PM EDT

16.06.2026

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, in South and Central America, the Caribbean, Russia and Commonwealth of Independent S.

08.06.2026

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

01.06.2026

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference.

07.05.2026

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.25 per share a year ago.

06.05.2026

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements. “We delivered a strong.

30.04.2026

Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates

Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.51. This compares to earnings of $2.22 per share a year ago.

09.04.2026

3 Bargain-Cheap Small Caps Worth a Second Look

The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's valuation. The average P/E ratio of stocks in the S&P 500 is around 27X.

Videos

No Data

There is no data to display

Press releases

16.06.2026

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

06.05.2026

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements. “We delivered a strong.

10.03.2026

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation. The score represents the highest rating in the small- and medium-sized enterprise (SME) category, achieved by only one other company in this year's report. The AMR Benchmark evaluates ph.

25.02.2026

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted select corporate progress and achievements. “202.

Innoviva, Inc. (INVA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Innoviva, Inc. (INVA)

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Innoviva to Participate in Upcoming Investor Conferences

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates

3 Bargain-Cheap Small Caps Worth a Second Look

Videos

No Data

Press releases

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Innoviva to Participate in Upcoming Investor Conferences

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates

3 Bargain-Cheap Small Caps Worth a Second Look

Videos

No Data

Press releases

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Search stocks

Innoviva, Inc. (INVA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Innoviva, Inc. (INVA)

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Innoviva to Participate in Upcoming Investor Conferences

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates

3 Bargain-Cheap Small Caps Worth a Second Look

Videos

No Data

Press releases

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Innoviva to Participate in Upcoming Investor Conferences

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates

3 Bargain-Cheap Small Caps Worth a Second Look

Videos

No Data

Press releases

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress